文献速递病毒性肝炎

在非洲和亚洲国家开发并现场评估用于开放多价平台的乙型肝炎病毒PCR以确定治疗资格:法国国家艾滋病与肝炎研究署12327研究结果

Development and field evaluation in African and Asian countries of an hepatitis B virus PCR on open polyvalent platforms to determine treatment eligibility: results from the "Agence Nationale de Recherche sur le Sida et les hépatites" 12327 study.
PubMed 文献 · Clin Microbiol Infect · 2024-05-11

研究在七个非洲和亚洲国家及法国实施开放多价平台上的定量HBV PCR(实验室自建法或CE-IVD版),并与Roche和Abbott参考检测比较。1015份样本显示结果一致性良好,与Roche和Abbott的平均差异(偏倚±标准差)分别为-0.3±0.7 log10 IU/mL和-0.2±0.9 log10 IU/mL,在A、B、C、D、E基因型中表现一致。

要点

  • 开放多价平台HBV PCR与Roche和Abbott参考检测结果一致性良好。
  • 与Roche比较平均差异为-0.3±0.7 log10 IU/mL,与Abbott为-0.2±0.9 log10 IU/mL。
  • 在>20 000至200 000 IU/mL和>200 000 IU/mL区间Kappa一致性几乎完美。

核心结论

  • 该现场评估显示此HBV PCR检测是专有PCR系统的有价值替代方案。
  • 开放平台上的PCR检测有助于扩展临床实验室解决方案,用于诊断符合抗病毒治疗病毒载量标准(>20 000 IU/mL)和母婴预防标准(>200 000 IU/mL)的个体。

研究设计与样本

  • 在七个非洲和亚洲国家及法国实施HBV PCR检测,使用实验室自建法或CE-IVD标记版PCR(Generic HBV Charge Virale, Biocentric)。
  • 将1015份样本的检测结果与参考检测(Roche Cobas AmpliPrep/Cobas TaqMan和Abbott RealTime on Abbott m2000)进行比较。

主要发现

  • 开放多价平台HBV PCR与参考检测的HBV DNA结果一致性良好,与Roche比较平均差异(偏倚±标准差)为-0.3±0.7 log10 IU/mL,与Abbott比较为-0.2±0.9 log10 IU/mL。
  • 开放多价平台HBV PCR与Roche/Abbott检测的Kappa-Cohen一致性在HBV DNA水平>20 000至200 000 IU/mL和>200 000 IU/mL区间几乎完美。
  • 在HBV DNA水平2000至20 000 IU/mL区间,与Abbott比较一致性为显著,与Roche比较为中等。
  • 该检测在基因型A、B、C、D和E中表现一致。

关键数值与推荐

  • WHO定义的临床显著HBV DNA阈值为2000 IU/mL、20 000 IU/mL和200 000 IU/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Widespread testing and treatment are essential to eliminate hepatitis B virus (HBV) infection as a public health concern. However, in resource-limited countries, access to HBV PCR is limited. In this study, we developed a quantitative HBV PCR assay on open molecular platforms and evaluate its performance in diagnosing clinically significant HBV DNA thresholds as defined by the WHO (2000 IU/mL, 20 000 IU/mL, and 200 000 IU/mL). METHODS: We implemented our HBV PCR test in seven African and Asian countries and France, using either an in-house laboratory method or a European conformity for in vitro diagnostic (CE-IVD) marked version of the PCR (Generic HBV Charge Virale, Biocentric). Results were compared with reference tests (Roche Cobas AmpliPrep/Cobas TaqMan and Abbott RealTime on Abbott m2000). RESULTS: There was a good agreement between the HBV DNA results of 1015 samples tested by the PCR on open polyvalent platforms and the results from reference tests (mean difference (bias ± standard deviation [SD]): -0.3 ± 0.7 log10 IU/mL and -0.2 ± 0.9 log10 IU/mL when compared with Roche and Abbott tests, respectively). Kappa-Cohen agreements between the HBV PCR on open polyvalent platforms and the Roche/Abbott assays appeared almost perfect for HBV DNA levels ranged from >20 000 to 200 000 IU/mL and >200 000 IU/mL, substantial and moderate for HBV DNA levels ranged from 2000 to 20 000 IU/mL when compared with Abbott and Roche, respectively. The assay's performance was consistent across genotypes A, B, C, D, and E. DISCUSSION: This field evaluation showed that our HBV PCR test is a valuable alternative to proprietary PCR systems. PCR assays on open platforms contribute to expanding clinical laboratory solutions for diagnosing individuals who meet the viral load criteria for antiviral therapy (>20 000 IU/mL) and mother-to-child prophylaxis (>200 000 IU/mL).

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Kania D, Nouhin J, Bolloré K, et al. Development and field evaluation in African and Asian countries of an hepatitis B virus PCR on open polyvalent platforms to determine treatment eligibility: results from the "Agence Nationale de Recherche sur le Sida et les hépatites" 12327 study. Clin Microbiol Infect. 2024. PMID: 38735369. doi:10.1016/j.cmi.2024.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。